{"id":62208,"date":"2026-04-02T21:18:11","date_gmt":"2026-04-02T13:18:11","guid":{"rendered":"https:\/\/flcube.com\/?p=62208"},"modified":"2026-04-02T21:18:12","modified_gmt":"2026-04-02T13:18:12","slug":"nmpa-approves-worlds-first-broad-spectrum-tumor-imaging-agent-99mtc-3prgd2-from-radio-medicinal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62208","title":{"rendered":"NMPA Approves World&#8217;s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal"},"content":{"rendered":"\n<p>China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted approval for <strong>99mTc-3PRGD2<\/strong>, a <strong>Category 1 radionuclide drug conjugate (RDC)<\/strong> developed by <strong>Radio Medicinal<\/strong>, marking the world&#8217;s first <strong>broad-spectrum tumor imaging agent<\/strong> for <strong>SPECT imaging diagnosis<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-approval-details\">Regulatory Approval Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Name<\/strong><\/td><td>99mTc-3PRGD2<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Category 1 RDC (innovative)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Radio Medicinal<\/td><\/tr><tr><td><strong>Parent Company<\/strong><\/td><td>Baheal Pharmaceutical Group (SHE: 301015)<\/td><\/tr><tr><td><strong>Approval Authority<\/strong><\/td><td>NMPA<\/td><\/tr><tr><td><strong>Primary Indication<\/strong><\/td><td>Auxiliary examination for regional lymph node metastasis in suspected lung cancer patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-amp-mechanism-of-action\">Technology &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-molecular-targeting\">Molecular Targeting<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Receptor<\/strong>: Integrin \u03b1v\u03b23<\/li>\n\n\n\n<li><strong>Molecular Probe<\/strong>: RGD peptide-based<\/li>\n\n\n\n<li><strong>Binding Specificity<\/strong>: Specifically binds to integrin \u03b1v\u03b23 receptors on:<\/li>\n\n\n\n<li>Tumor cells<\/li>\n\n\n\n<li>Tumor neovascular endothelial cells<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-imaging-capabilities\">Imaging Capabilities<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Modality<\/strong>: SPECT (Single Photon Emission Computed Tomography)<\/li>\n\n\n\n<li><strong>Precision<\/strong>: Enables precise tumor imaging through targeted molecular binding<\/li>\n\n\n\n<li><strong>Spectrum<\/strong>: Broad-spectrum applicability across multiple tumor types expressing integrin \u03b1v\u03b23<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-amp-corporate-background\">Development &amp; Corporate Background<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-radio-medicinal-profile\">Radio Medicinal Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Specialization<\/strong>: Nuclear medicine innovation enterprise<\/li>\n\n\n\n<li><strong>Investment Structure<\/strong>: Incubated and invested by Baheal Pharmaceutical Group<\/li>\n\n\n\n<li><strong>Strategic Focus<\/strong>: Development of novel radiopharmaceuticals and molecular imaging agents<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-baheal-pharmaceutical-group\">Baheal Pharmaceutical Group<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Stock Exchange<\/strong>: Shenzhen Stock Exchange (SHE: 301015)<\/li>\n\n\n\n<li><strong>Investment Strategy<\/strong>: Strategic incubation of specialized biotech companies in nuclear medicine<\/li>\n\n\n\n<li><strong>Portfolio Expansion<\/strong>: Entry into diagnostic radiopharmaceuticals complements existing therapeutic portfolio<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-amp-market-implications\">Clinical &amp; Market Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-diagnostic-advancement\">Diagnostic Advancement<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need Addressed<\/strong>: Improved detection of lymph node metastasis in lung cancer suspects<\/li>\n\n\n\n<li><strong>Clinical Utility<\/strong>: Provides physicians with precise imaging tool for staging and treatment planning<\/li>\n\n\n\n<li><strong>Broad Applicability<\/strong>: Potential expansion to other integrin \u03b1v\u03b23-expressing tumors beyond lung cancer<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-positioning\">Market Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Status<\/strong>: World&#8217;s first broad-spectrum tumor imaging agent creates significant competitive advantage<\/li>\n\n\n\n<li><strong>Category 1 Designation<\/strong>: Highest innovation classification in China supports premium pricing and market exclusivity<\/li>\n\n\n\n<li><strong>Nuclear Medicine Growth<\/strong>: Aligns with global trend toward precision molecular diagnostics in oncology<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Innovation<\/strong>: Demonstrates China&#8217;s growing capability in advanced radiopharmaceutical development<\/li>\n\n\n\n<li><strong>Diagnostic-Therapeutic Integration<\/strong>: Potential for theranostic applications combining diagnosis and targeted therapy<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: First-in-world status positions product for international regulatory submissions<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding market opportunities, clinical applications, and regulatory pathways. Actual commercial performance may vary based on market adoption, reimbursement policies, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s National Medical Products Administration (NMPA) has granted approval for 99mTc-3PRGD2, a Category 1 radionuclide&#8230;<\/p>\n","protected":false},"author":1,"featured_media":62209,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4675],"class_list":["post-62208","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-radio-medicinal"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA Approves World&#039;s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s National Medical Products Administration (NMPA) has granted approval for 99mTc-3PRGD2, a Category 1 radionuclide drug conjugate (RDC) developed by Radio Medicinal, marking the world&#039;s first broad-spectrum tumor imaging agent for SPECT imaging diagnosis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62208\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Approves World&#039;s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal\" \/>\n<meta property=\"og:description\" content=\"China&#039;s National Medical Products Administration (NMPA) has granted approval for 99mTc-3PRGD2, a Category 1 radionuclide drug conjugate (RDC) developed by Radio Medicinal, marking the world&#039;s first broad-spectrum tumor imaging agent for SPECT imaging diagnosis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62208\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-02T13:18:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-02T13:18:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0201-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62208#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62208\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Approves World&#8217;s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal\",\"datePublished\":\"2026-04-02T13:18:11+00:00\",\"dateModified\":\"2026-04-02T13:18:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62208\"},\"wordCount\":362,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62208#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0201-1.webp\",\"keywords\":[\"Radio Medicinal\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62208#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62208\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62208\",\"name\":\"NMPA Approves World's First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62208#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62208#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0201-1.webp\",\"datePublished\":\"2026-04-02T13:18:11+00:00\",\"dateModified\":\"2026-04-02T13:18:12+00:00\",\"description\":\"China's National Medical Products Administration (NMPA) has granted approval for 99mTc-3PRGD2, a Category 1 radionuclide drug conjugate (RDC) developed by Radio Medicinal, marking the world's first broad-spectrum tumor imaging agent for SPECT imaging diagnosis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62208#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62208\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62208#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0201-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0201-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"NMPA Approves World's First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62208#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Approves World&#8217;s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Approves World's First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal - Insight, China&#039;s Pharmaceutical Industry","description":"China's National Medical Products Administration (NMPA) has granted approval for 99mTc-3PRGD2, a Category 1 radionuclide drug conjugate (RDC) developed by Radio Medicinal, marking the world's first broad-spectrum tumor imaging agent for SPECT imaging diagnosis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62208","og_locale":"en_US","og_type":"article","og_title":"NMPA Approves World's First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal","og_description":"China's National Medical Products Administration (NMPA) has granted approval for 99mTc-3PRGD2, a Category 1 radionuclide drug conjugate (RDC) developed by Radio Medicinal, marking the world's first broad-spectrum tumor imaging agent for SPECT imaging diagnosis.","og_url":"https:\/\/flcube.com\/?p=62208","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-02T13:18:11+00:00","article_modified_time":"2026-04-02T13:18:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0201-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62208#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62208"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Approves World&#8217;s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal","datePublished":"2026-04-02T13:18:11+00:00","dateModified":"2026-04-02T13:18:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62208"},"wordCount":362,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=62208#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0201-1.webp","keywords":["Radio Medicinal"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62208#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62208","url":"https:\/\/flcube.com\/?p=62208","name":"NMPA Approves World's First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=62208#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=62208#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0201-1.webp","datePublished":"2026-04-02T13:18:11+00:00","dateModified":"2026-04-02T13:18:12+00:00","description":"China's National Medical Products Administration (NMPA) has granted approval for 99mTc-3PRGD2, a Category 1 radionuclide drug conjugate (RDC) developed by Radio Medicinal, marking the world's first broad-spectrum tumor imaging agent for SPECT imaging diagnosis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62208#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62208"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=62208#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0201-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0201-1.webp","width":1080,"height":608,"caption":"NMPA Approves World's First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62208#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Approves World&#8217;s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0201-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62208"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62208\/revisions"}],"predecessor-version":[{"id":62210,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62208\/revisions\/62210"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/62209"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}